Proton pump inhibitor formulary considerations in the acutely ill. Part 2: Clinical efficacy, safety, and economics

John W. Devlin, Lynda S. Welage, Keith M. Olsen

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

OBJECTIVE: To review, using an evidence-based approach, the clinical efficacy, safety, and cost-effectiveness of proton pump inhibitors (PPIs) for treatment of common acid peptic disorders in the acutely ill and provide clinicians with guidance when making hospital formulary decisions with this class of agents. DATA SOURCES: MEDLINE (1966-May 2005) and the Cochrane Library databases were searched using the key words proton pump inhibitor, acid suppression, peptic ulcer disease, gastrointestinal bleeding, stress ulcer prophylaxis, critical care, safety, and cost-effectiveness. Bibliographies of cited references were reviewed, and a manual search of abstracts from recent gastroenterology, critical care, and surgery scientific meetings was completed. STUDY SELECTION AND DATA EXTRACTION: All articles identified from the data sources were evaluated, and all information deemed relevant was included for this review. DATA SYNTHESIS: PPIs have become a mainstay for acute acid suppression in hospitalized patients. Various commercially available PPI products are available either enterally or parenterally for administration to patients unable to swallow a tablet or capsule. The results of studies comparing the clinical efficacy of different PPI dosage forms and routes of administration, safety considerations, and cost-effectiveness analyses are among the factors to consider when making formulary decisions for this class of drugs. CONCLUSIONS: While the introduction of new PPI products has expanded the therapeutic options for acid suppression in acutely ill patients, a number of unresolved questions remain surrounding the interchangeability of these products, the clinical significance of one PPI formulation over the other, and how oral/enteral therapy should be used as step-down therapy after parenteral therapy.

Original languageEnglish (US)
Pages (from-to)1844-1851
Number of pages8
JournalAnnals of Pharmacotherapy
Volume39
Issue number11
DOIs
StatePublished - Nov 1 2005

Fingerprint

Formularies
Proton Pump Inhibitors
Economics
Safety
Cost-Benefit Analysis
Acids
Information Storage and Retrieval
Critical Care
Hospital Formularies
Therapeutics
Gastrointestinal Diseases
Dosage Forms
Bibliography
Gastroenterology
Deglutition
Peptic Ulcer
MEDLINE
Tablets
Libraries
Small Intestine

Keywords

  • Lansoprazole
  • Omeprazole
  • Pantoprazole
  • Proton pump inhibitors: esomeprazole
  • Rabeprazole
  • Stress ulcer prophylaxis

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Proton pump inhibitor formulary considerations in the acutely ill. Part 2 : Clinical efficacy, safety, and economics. / Devlin, John W.; Welage, Lynda S.; Olsen, Keith M.

In: Annals of Pharmacotherapy, Vol. 39, No. 11, 01.11.2005, p. 1844-1851.

Research output: Contribution to journalReview article

Devlin, John W. ; Welage, Lynda S. ; Olsen, Keith M. / Proton pump inhibitor formulary considerations in the acutely ill. Part 2 : Clinical efficacy, safety, and economics. In: Annals of Pharmacotherapy. 2005 ; Vol. 39, No. 11. pp. 1844-1851.
@article{e85ea185269a4b8faab5e3278b8acfb6,
title = "Proton pump inhibitor formulary considerations in the acutely ill. Part 2: Clinical efficacy, safety, and economics",
abstract = "OBJECTIVE: To review, using an evidence-based approach, the clinical efficacy, safety, and cost-effectiveness of proton pump inhibitors (PPIs) for treatment of common acid peptic disorders in the acutely ill and provide clinicians with guidance when making hospital formulary decisions with this class of agents. DATA SOURCES: MEDLINE (1966-May 2005) and the Cochrane Library databases were searched using the key words proton pump inhibitor, acid suppression, peptic ulcer disease, gastrointestinal bleeding, stress ulcer prophylaxis, critical care, safety, and cost-effectiveness. Bibliographies of cited references were reviewed, and a manual search of abstracts from recent gastroenterology, critical care, and surgery scientific meetings was completed. STUDY SELECTION AND DATA EXTRACTION: All articles identified from the data sources were evaluated, and all information deemed relevant was included for this review. DATA SYNTHESIS: PPIs have become a mainstay for acute acid suppression in hospitalized patients. Various commercially available PPI products are available either enterally or parenterally for administration to patients unable to swallow a tablet or capsule. The results of studies comparing the clinical efficacy of different PPI dosage forms and routes of administration, safety considerations, and cost-effectiveness analyses are among the factors to consider when making formulary decisions for this class of drugs. CONCLUSIONS: While the introduction of new PPI products has expanded the therapeutic options for acid suppression in acutely ill patients, a number of unresolved questions remain surrounding the interchangeability of these products, the clinical significance of one PPI formulation over the other, and how oral/enteral therapy should be used as step-down therapy after parenteral therapy.",
keywords = "Lansoprazole, Omeprazole, Pantoprazole, Proton pump inhibitors: esomeprazole, Rabeprazole, Stress ulcer prophylaxis",
author = "Devlin, {John W.} and Welage, {Lynda S.} and Olsen, {Keith M.}",
year = "2005",
month = "11",
day = "1",
doi = "10.1345/aph.1G176",
language = "English (US)",
volume = "39",
pages = "1844--1851",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "11",

}

TY - JOUR

T1 - Proton pump inhibitor formulary considerations in the acutely ill. Part 2

T2 - Clinical efficacy, safety, and economics

AU - Devlin, John W.

AU - Welage, Lynda S.

AU - Olsen, Keith M.

PY - 2005/11/1

Y1 - 2005/11/1

N2 - OBJECTIVE: To review, using an evidence-based approach, the clinical efficacy, safety, and cost-effectiveness of proton pump inhibitors (PPIs) for treatment of common acid peptic disorders in the acutely ill and provide clinicians with guidance when making hospital formulary decisions with this class of agents. DATA SOURCES: MEDLINE (1966-May 2005) and the Cochrane Library databases were searched using the key words proton pump inhibitor, acid suppression, peptic ulcer disease, gastrointestinal bleeding, stress ulcer prophylaxis, critical care, safety, and cost-effectiveness. Bibliographies of cited references were reviewed, and a manual search of abstracts from recent gastroenterology, critical care, and surgery scientific meetings was completed. STUDY SELECTION AND DATA EXTRACTION: All articles identified from the data sources were evaluated, and all information deemed relevant was included for this review. DATA SYNTHESIS: PPIs have become a mainstay for acute acid suppression in hospitalized patients. Various commercially available PPI products are available either enterally or parenterally for administration to patients unable to swallow a tablet or capsule. The results of studies comparing the clinical efficacy of different PPI dosage forms and routes of administration, safety considerations, and cost-effectiveness analyses are among the factors to consider when making formulary decisions for this class of drugs. CONCLUSIONS: While the introduction of new PPI products has expanded the therapeutic options for acid suppression in acutely ill patients, a number of unresolved questions remain surrounding the interchangeability of these products, the clinical significance of one PPI formulation over the other, and how oral/enteral therapy should be used as step-down therapy after parenteral therapy.

AB - OBJECTIVE: To review, using an evidence-based approach, the clinical efficacy, safety, and cost-effectiveness of proton pump inhibitors (PPIs) for treatment of common acid peptic disorders in the acutely ill and provide clinicians with guidance when making hospital formulary decisions with this class of agents. DATA SOURCES: MEDLINE (1966-May 2005) and the Cochrane Library databases were searched using the key words proton pump inhibitor, acid suppression, peptic ulcer disease, gastrointestinal bleeding, stress ulcer prophylaxis, critical care, safety, and cost-effectiveness. Bibliographies of cited references were reviewed, and a manual search of abstracts from recent gastroenterology, critical care, and surgery scientific meetings was completed. STUDY SELECTION AND DATA EXTRACTION: All articles identified from the data sources were evaluated, and all information deemed relevant was included for this review. DATA SYNTHESIS: PPIs have become a mainstay for acute acid suppression in hospitalized patients. Various commercially available PPI products are available either enterally or parenterally for administration to patients unable to swallow a tablet or capsule. The results of studies comparing the clinical efficacy of different PPI dosage forms and routes of administration, safety considerations, and cost-effectiveness analyses are among the factors to consider when making formulary decisions for this class of drugs. CONCLUSIONS: While the introduction of new PPI products has expanded the therapeutic options for acid suppression in acutely ill patients, a number of unresolved questions remain surrounding the interchangeability of these products, the clinical significance of one PPI formulation over the other, and how oral/enteral therapy should be used as step-down therapy after parenteral therapy.

KW - Lansoprazole

KW - Omeprazole

KW - Pantoprazole

KW - Proton pump inhibitors: esomeprazole

KW - Rabeprazole

KW - Stress ulcer prophylaxis

UR - http://www.scopus.com/inward/record.url?scp=27344452930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27344452930&partnerID=8YFLogxK

U2 - 10.1345/aph.1G176

DO - 10.1345/aph.1G176

M3 - Review article

C2 - 16204393

AN - SCOPUS:27344452930

VL - 39

SP - 1844

EP - 1851

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 11

ER -